Xolair 150 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FCRV3
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $78,961
Award facts
- Contract value 100% obligated
- $78,961.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a $78,961 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. for XOLAIR 150 mg/ml syringes, awarded on January 20, 2026, with an ultimate completion date of February 10, 2026. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected without a set-aside designation, demonstrating the company's competitive capability in unrestricted federal procurement. The delivery order will be performed in Park Ridge, Illinois, and represents one of numerous orders issued to the vendor under the Pharmaceutical Prime Vendor Global Program Generation V initiative.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Medical Supply Chain division, designated SPE2DR, which was awarded in November 2025 with a $499,999,999 ceiling value and completion date of December 31, 2036. The PPV-G GEN V program is a $30.3 billion strategic acquisition vehicle designed to supply comprehensive pharmaceutical products, biologics, and medical consumables to Department of Defense military healthcare facilities worldwide. XOLAIR is a biologic immunosuppressant agent used in the treatment of asthma and allergic conditions, and this delivery order supports the recurring pharmaceutical supply requirements of the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FCRV3?
SPE2DR26FCRV3 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 20, 2026.
How much is contract SPE2DR26FCRV3 worth?
The government has obligated $78,961 on SPE2DR26FCRV3.
Is contract SPE2DR26FCRV3 an order under another contract?
Yes. SPE2DR26FCRV3 is a delivery order under SPE2DR25D9168, an indefinite delivery contract.
Was contract SPE2DR26FCRV3 competed?
The extent of competition for SPE2DR26FCRV3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award